TherapeuticsMD Inc (NYSEMKT:TXMD) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Friday.

Several other analysts also recently issued reports on the stock. Morgan Stanley started coverage on shares of TherapeuticsMD in a report on Friday, September 8th. They set an “equal weight” rating and a $6.00 price objective for the company. Oppenheimer Holdings, Inc. raised shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $18.93.

TherapeuticsMD (NYSEMKT:TXMD) traded down 2.14% during midday trading on Friday, reaching $4.58. 2,067,153 shares of the company traded hands. TherapeuticsMD has a 12 month low of $4.54 and a 12 month high of $8.30. The firm has a 50 day moving average of $4.87 and a 200-day moving average of $4.87. The stock’s market capitalization is $934.44 million.

WARNING: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NYSEMKT:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with's FREE daily email newsletter.